| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 1 | 1999 | Impact of the treating institution on survival of patients with "poor progosis" metastatic nonseminoma | Collette, L.; SYLVESTER, Richard; Stenning, S.P.; Fossa, S.D.; Mead, G.M.; de Wit, R.; de Mulder, P.H.M.; Neymark, N.; Lallemand, E.; Kaye, S.B. | Journal Contribution | |
| 2 | 1998 | Serum alpha-fetoprotein surge after the iniation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance | SYLVESTER, Richard; de Wit, R.; Collette, L.; de Mulder, P.H.M.; Sleijfer, D.T.; ten Bokkel Huinink, W.W.; Kaye, S.B.; van Oosterom, A.T.; Boven, E.; Stoter, G. | Journal Contribution | |
| 3 | 1998 | Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study | Kaye, S.B.; Mead, G.M.; Fossa, S.; Cullen, M.; de Wit, R.; Bodrogi, I.; van Groeningen, C.; SYLVESTER, Richard; Collette, L.; Stenning, S.; de Prijck, L.; Lallemand, E. | Journal Contribution | |
| 4 | 1997 | Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multi-institutional Medical Research Council/ European Organization for Research and Treatment of Cancer Trial | Horwich, A.; Sleijfer, D.T.; Fossa, S.D.; Kaye, S.B.; Oliver, R.T.D.; Cullen, M.H.; Mead, G.M.; de Wit, R.; de Mulder, P.H.M.; Dearnaley, D.P.; Cook, P.A.; Stenning, S.P.; SYLVESTER, Richard | Journal Contribution | |
| 5 | 1997 | Importance of bleomycin in combination chemotherapy for good prognosis testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group | de Wit, R.; Stoter, G.; Kaye, S.B.; Steijffer, D.Th.; Jones, W.G.; ten Bokkel Huinink, W.W.; Rea, L.A.; Collette, L.; SYLVESTER, Richard | Journal Contribution | |
| 6 | 1997 | Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminatomous testicular cancer | de Wit, R.; SYLVESTER, Richard; Tsitsa, C.; de Mulder, P.H.M.; Sleyfer, D.T.; ten Bokkel Huinink, W.W.; Kaye, S.B.; van Oosterom, A.T.; Boven, E.; Stoter, G. | Journal Contribution | |
| 7 | 1991 | Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery | Jansen, R.L.H.; SYLVESTER, Richard; Sleyfer, D.T.; ten Bokkel Huinink, W.W.; Kaye, S.B.; Jones, W.G.; Keizer, J.; van Oosterom, A.T.; Meyer, S.; Vendrik, C.P.J.; de Pauw, M.; Stoter, G. | Journal Contribution | |